JP2019504868A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504868A5
JP2019504868A5 JP2018543090A JP2018543090A JP2019504868A5 JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5 JP 2018543090 A JP2018543090 A JP 2018543090A JP 2018543090 A JP2018543090 A JP 2018543090A JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5
Authority
JP
Japan
Prior art keywords
virus
vector according
viral vector
sequence
grna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543090A
Other languages
English (en)
Japanese (ja)
Other versions
JP7176737B2 (ja
JP2019504868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/017652 external-priority patent/WO2017142835A1/en
Publication of JP2019504868A publication Critical patent/JP2019504868A/ja
Publication of JP2019504868A5 publication Critical patent/JP2019504868A5/ja
Application granted granted Critical
Publication of JP7176737B2 publication Critical patent/JP7176737B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543090A 2016-02-15 2017-02-13 レトロウイルス核酸配列の切除 Expired - Fee Related JP7176737B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662295390P 2016-02-15 2016-02-15
US62/295,390 2016-02-15
US201662298722P 2016-02-23 2016-02-23
US62/298,722 2016-02-23
US201662337994P 2016-05-18 2016-05-18
US62/337,994 2016-05-18
US201662345520P 2016-06-03 2016-06-03
US62/345,520 2016-06-03
US201662363625P 2016-07-18 2016-07-18
US62/363,625 2016-07-18
US201662410496P 2016-10-20 2016-10-20
US62/410,496 2016-10-20
PCT/US2017/017652 WO2017142835A1 (en) 2016-02-15 2017-02-13 Excision of retroviral nucleic acid sequences

Publications (3)

Publication Number Publication Date
JP2019504868A JP2019504868A (ja) 2019-02-21
JP2019504868A5 true JP2019504868A5 (enExample) 2020-03-26
JP7176737B2 JP7176737B2 (ja) 2022-11-22

Family

ID=59626223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018543090A Expired - Fee Related JP7176737B2 (ja) 2016-02-15 2017-02-13 レトロウイルス核酸配列の切除

Country Status (9)

Country Link
US (2) US12122997B2 (enExample)
EP (1) EP3417062B1 (enExample)
JP (1) JP7176737B2 (enExample)
CN (1) CN109415728A (enExample)
AU (1) AU2017219605B2 (enExample)
CA (1) CA3014631A1 (enExample)
MX (2) MX2018009904A (enExample)
WO (1) WO2017142835A1 (enExample)
ZA (2) ZA201806060B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
SG10201914137YA (en) 2015-06-01 2020-02-27 Univ Temple Methods and compositions for rna-guided treatment of hiv infection
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3417062B1 (en) 2016-02-15 2024-06-26 Temple University - Of The Commonwealth System of Higher Education Excision of retroviral nucleic acid sequences
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
CN113528514B (zh) * 2020-04-22 2023-05-05 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas12a干预阻断病毒逆转录转座的技术
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2022071974A1 (en) * 2020-10-02 2022-04-07 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of herpes simplex type i and other related human herpesviruses
CA3218209A1 (en) * 2021-04-28 2022-11-03 Salk Institute For Biological Studies Multiplex crispr/cas9-mediated target gene activation system
US20240271112A1 (en) * 2021-06-01 2024-08-15 University Of Massachusetts Cas9 nickase-mediated gene editing
WO2023010061A1 (en) * 2021-07-27 2023-02-02 University Of Miami Nanoparticles and uses thereof for treatment of human immunodeficiency virus
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
WO2026039311A1 (en) 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
WO2011043830A2 (en) 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
SG10201707569YA (en) * 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
AU2014312123A1 (en) * 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
CN104726449A (zh) 2015-03-23 2015-06-24 国家纳米科学中心 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途
EP3417062B1 (en) 2016-02-15 2024-06-26 Temple University - Of The Commonwealth System of Higher Education Excision of retroviral nucleic acid sequences

Similar Documents

Publication Publication Date Title
Pal et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A* 01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency
Merten et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application
KR102423444B1 (ko) 레트로바이러스 벡터
Hofmann et al. Species-specific, postentry barriers to primate immunodeficiency virus infection
Doria-Rose et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge
Aguchi et al. Sequence Note: Identification of a New HIV-2 Subtype Based on Phylogenetic Analysis of Full-Length Genomic Sequence
RU2018130640A (ru) Способы и композиции для направляемого рнк лечения вич-инфекции
Casimiro et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
JP2018516572A5 (enExample)
Evans et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239
Takeda et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model
CA2387182A1 (en) Lentiviral vectors for the preparation of immunotherapeutical compositions
JP2019527055A5 (enExample)
JP2018524335A5 (enExample)
DK33190D0 (da) Hiv-3 retrovirus og anvendelse heraf
RU2009130342A (ru) Применение адаптированных рекомбиназ для лечения ретровирусных инфекций
Hammonds et al. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization
JP2003514565A5 (enExample)
Patterson et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120
Mansfield et al. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Otten et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles
CN104039968A (zh) 非b亚型gag蛋白在慢病毒包装中的应用
Lim et al. Specific insertions of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration properties
Tsukamoto et al. Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques